FDA Takes Second Stab At Multivariate Diagnostic Oversight Guidelines
This article was originally published in The Gray Sheet
Executive Summary
FDA cautiously moved ahead with its controversial plan to actively regulate certain laboratory-developed tests with the release of a revised 1draft guidance document July 24
You may also be interested in...
Mass-Spec Dx Makers Should Look To FDA's Multiplex, Multivariate Approach For Regulatory Tips
As FDA develops a framework for liquid chromatography-mass spectrometry diagnostics, the agency's previously circulated policies on multiplex test instrument systems and in vitro diagnostic multivariate index assays offer hints as to what LC-MS companies can expect.
LabCorp Pulls OvaSure, But Charges FDA With Overreaching
Laboratory Corporation of America pulled its early-stage ovarian cancer test service from the market last week in response to FDA scrutiny, but the lab giant called the agency's actions leading up to the withdrawal "unprecedented.
LabCorp Pulls OvaSure, But Charges FDA With Overreaching
Laboratory Corporation of America pulled its early-stage ovarian cancer test service from the market last week in response to FDA scrutiny, but the lab giant called the agency's actions leading up to the withdrawal "unprecedented.